Since joining Driscoll in 2024, he has expanded pediatric urology offerings, including new technologies that enable faster ...

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, Anktiva. Read more here.

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...

Stories of Strength” will be held March 23 at the Newman Center, 90 Broad St., Plattsburgh, from 6 to 7:30 pm. “The Coalition to Prevent Suicide had ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ...

ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...

CEO Richard Adcock said physicians could prescribe Anktiva for papillary bladder cancer if it is added to NCCN treatment guidelines. ・The company recently filed a supplemental biologics license ...

Biesterfeld has just started to distribute Lynxter S300X – LIQ21 | LIQ11, an industrial Independent dual extruder (IDEX) 3D ...

GLEN DALE, W.Va. — Reynolds Memorial Hospital has performed its first implantation of the Altaviva device, a new treatment option designed to help manage bladder control symptoms.Hospital officials ...

This year's market swings have investors turning to dividend-paying stocks. While the S & P 500 is in the green on Monday, the broad market index has now lost about 2% in 2026 as the Iran war led to a ...